Opioids, Glucocorticoids, Anesthetics, Adjuvants (Week 2--Melega) Flashcards
WHO analgesic ladder
Way to approach how to give pain medication
1) Non-opioid +/- adjuvant
2) Opioid for mild to moderate pain + non-opioid +/- adjuvant
3) Opioid for moderate to severe pain +/- non-opioid +/- adjuvant
Opium
Extract of the juice of the poppy
Consists of 20 different compounds, including morphine and codeine
Opiates vs. opioids
Opiates are natural compounds isolated from opium (morphine and codeine)
Opioids are generic name for natural, semi-synthetic and synthetic compounds related to opium
(opiates ARE opioids)
Narcotics
Strictly refers to psychoactive compound with morphine-like effects
Inaccurate term because implies narcosis which is not necessarily produced by therapeutic doses
Narcotics are by law illegal or designated as controlled substances
Do we have endogenous opioid-like compounds in our bodies?
Yes, that’s why we have receptors for opioids
Beta-endorphin
Leucine- and methionine-enkaphalin
Dynorphins
How are opioids effective analgesics?
Opioids act as agonists and mimick analgesic activity endogenous compounds have
Bind to receptors on neuronal elements which allow them to function as NTs or neuromoduators
Modulate pain transmission at peripheral nociceptive afferents in spinal cord and brain
Endogenous opioid peptide receptors
All have inhibitory functions (however, can inhibit an inhibitory neuron to activate a process), all are G protein-coupled
Mu receptors
Kappa receptors
Delta receptors
3 mechanisms of opioid inhibition
1) Inhibit adenylate cyclase (decrease cAMP)
2) Reduce Ca2+ influx (thus reduce NT release)
3) Increase K+ efflux (hyperpolarized postsynaptic neuron)
Which neurons do opioids bind to?
Opioids bind to ascending pain transmission neurons to inhibit ascending nociceptive activity
Opioids bind to inhibitory neurons to cause disinhibition (activation) of descending pathways that then inhibit ascending nociceptive activity
CNS efects produced by Mu opioid agonists
1) Analgesia: symptomatic relief of pain that does not produce hypnosis (sleep) or impair sensation
2) Euphoria: mood elevation, sometimes frank euphoria, sometimes dysphoria
3) Sedation and drowsiness: dose-dependent drowsiness, feeling of heaviness, difficulty concentrating are common at first
4) Miosis: (NOT directly on PNS) Edinger-Westphal nucleus of third nerve contains para pre cell bodies and is inhibited by local interneurons, but opioids bind these and inhibit interneurons to activate E-W nucleus and cause too much para pre stimulation
5) Respiratory depression: decreased sensitivity of respiratory center in medulla to increases in blood CO2 (this is always cause of death from OD)
6) Nausea and vomiting: stimulate CTZ
7) Cough suppression: (antitussive) by acting on “cough center” in medulla
8) Inhibition of neuroendocrine factors: inhibit GnRH, CRH in hypothalamus (decrease plasma LH, FSH, ACTH, beta-endorphin)
Peripheral nervous system effects produced by Mu opioid agonists
1) Constipation: increased resting tone in GI
2) Constriction of sphincter of Oddi
3) Urinary retention: decreased force of detrusor muscle contraction
4) Histamine release from tissue mast cells and circulating basophils: causes itching, flushing, wamer skin, bronchoconstriction; morphine/codeine/meperidine can cause non-immunologic displacement of histamine from tissue mast cells
5) Truncal rigidity: only with large IV doses of a few drugs (fentanyl and congeners)
Classification of opioid medications
Agonist (strong, moderate, weak)
Mixed agonist-antagonist
Antagonist
Strong Mu agonists
Morphine
Hydromorphone (Dilaudid; “moderate to strong” but more potent than morphine!)
Fentanyl (Sublimaze; mu and kappa agonist, 80x more potent than morphine)
Methadone (also NMDA antagonist; good ORAL)
Moderate Mu agonists
Codeine
Oxycodone (Oxycontin; “moderate to strong”)
Meperidine (Demerol; “moderate to strong” but 6x less potent than morphine)
Hydrocodone
Weak Mu agonists
Propoxyphene (taken off market)
Tramadol (works at opioid receptors but not actually an opioid derivative)
Anti-diarrhea Opioids
Loperamide (Immodium)
Diphenoxylate (Lomotil)
Act as mu receptor agonists in myemteric plexus of large intestine to decrease GI motor activity and increase sphincter tone
Don’t affect CNS like other opioids do, don’t cross BBB much and whatever does is effluxed from brain by P-glycoprotein
Mixed opioid agonist-antagonists
Ex: pentazocine
Point was to make drug with analgesic but less addictive qualities (people still abused these though)
Occasional dysphoria or hallucination with kappa agonists
Ceiling effect for respiratory depression
Competitive antagonists or agonists at mu receptor and agonists at kappa or delta receptor
Symptoms of opioid overdose
Toxic triad: coma, pinpoint pupils, depressed respiration
Hypotension, hypothermia (skin cold and clammy), urinary retention, skeletal muscles flaccid, pulmonary edema, bradycardia, seizures (rarely)
Most signs of opioid intoxication reversed by naloxone
Classifications of opioid drugs
Agonists: morphine, codeine, heroine, hydromorphone, oxycodone, hydrocodone, meperidine, fentanyl, methadone, propoxyphene, tramadol
Mixed agonist-antagonist: pentazocine
Partial agonist: buprenorphine
Diarrhea treatment: loperamide, diphenoxylate
Opioid antagonists: naloxone, naltrexone
Antitussive: dextromethorphan
3 types of tolerance
1) Pharmacokinetic (dispositional): changes in absorption, metabolism or elimination so plasma AUC lower than observed initially
2) Pharmacodynamic: down-regulation of receptors, changes in receptor-effector coupling, compensatory physiological changes; desensitization
3) Cross-tolerance: resistance to one or several effects of a compound as a result of tolerance developed to a pharmacologically similar compound
Opioid tolerance
Can develop when large doses of opioids administered at short time intervals
First indication of tolerance is decreased duration of analgesia then decreased intensity of effect
Little or no tolerance for constipating effects of opioid agonists
Physical dependence
When drug is needed for normal physiological homeostasis (is universal with prolonged opioid therapy)
Must taper off opioids to avoid withdrawal syndrome
Cannot directly assess physical dependence but know they have it if there is withdrawal syndrome upon discontinuation of drug then elimination of symptoms upon readministration of drug
Opioid withdrawal
Like the worst symptoms of a bad cold
Yawning, lacrimation, rhinorrhea, sweating, gooseflesh/piloerection (“go cold turkey”), chills, anxiety, nausea, vomiting, diarrhea, hyperactive bowel sounds, abdominal cramps
Without treatment, get insomnia, anorexia, muscle crapms/spasms in legs and back (“kicking the habit”), dilated pupils, tachycardia, HTN
Withdrawal symptoms begin after 8-10 hours and last 7-10 days
Pseudoaddicton
Drug seeking, increased focus on obtaining medications, patients with poorly managed pain mimic the signs of psychological dependence, but pseudoaddiction resolves with effective pain management
Can be exacerbated by curtailing opioid therapy (because person will be in more pain)
Addiction
Defined by WHO as behavioral pattern of drug use, characterized by involvement with compulsive use of drug, securing its supply, high tendency to relapse after withdrawal
Who is at risk for drug addiction and how do we tell?
History: personal, family hx drug abuse, current addiction, hx problems with prescriptions, comorbid psychiatric disorders
Screening instruments: scored clinical surveys like opioid risk tool (ORT)
Behavioral checklists
Therapeutic maneuver (if functioning improves upon increased opiod dose it’s fine, but if not probably addicted)
What should we document in the patient’s chart?
Why opioid is prescribed
What reduction in pain has been achieved
What functional improvement has occurred
Document acceptable side effects
Document responsible medication use and absence of aberrant behavior
Corticosteroids
Anti-inflammatory and immunosuppressive
Inhibit synthesis of inflammatory proteins, cytokines, by inhibiting phospholipase A2 (eicosanoid pathway completely inhibited, so no prostaglandins and no leukotrienes)
Use is limited by systemic side effects
Glucocorticoid action on gene expression
GC enters cell and binds to cytoplasmic glucocorticoid receptor that is complexed with two HSP molecules –> GR translocates to nucleus where binds as a dimer to glucocorticoid recognition sequence (GRE) upstream of promoter –> increased transcription of anti-inflammatory genes
Similar pathway to inhibit transcription of inflammatory genes (cytokines, enzymes, receptors, adhesion molecules) using nGRE upstream sequence
Note: both increases and decreases in transcriptional rates of genes associated with inflammation
Non-genomic effects of glucocorticoids
Rapid effects which occur within a few minutes, actions do not require de novo protein synthesis
Modulate degree of activation and responsiveness of target cells (monocytes, T cells, platelets)
Unclear how these effects contribute to therapeutic efficacy of GCs in controlling vascular inflammatory pathology